Rufinamide oral suspension approved for seizures
The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.
The FDA has approved rufinamide oral suspension 40 mg/mL as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy.
Lennox-Gastaut syndrome usually begins before 4 years of age as a result of brain malformations, severe head injury, perinatal asphyxia, central nervous system infection, or inherited degenerative or metabolic disorders. Patients may experience frequent seizures. One-third of cases present with no perceivable causes.
Children with LGS display developmental delays and impaired intellectual function, information processing, and behavior.
Rufinamide is approved for children 4 years of age and older and adults. The new oral suspension benefits patients who prefer a liquid or who find tablets difficult to swallow.
